Can Novartis Break Back Into The US Top Five? It Is Going To Need Bigger Blockbusters

New Strategy Head Will Seek Higher Earning Innovation

 
• By Andrew McConaghie
  
Novartis
Novartis is the leader in number of new approvals in recent years - but does not have a big-earning blockbuster like Trulicity or Keytruda to power its US sales. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip